Protalix BioTherapeutics, Inc.
PLX
$1.67
$0.000.00%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.60% | 16.21% | 169.82% | 73.74% | 73.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.60% | 16.21% | 169.82% | 73.74% | 73.60% |
| Cost of Revenue | -0.61% | -37.92% | 214.37% | -56.12% | 71.16% |
| Gross Profit | -0.59% | 143.60% | 68.67% | 779.26% | 75.79% |
| SG&A Expenses | 12.87% | -24.68% | -16.44% | -27.61% | -29.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.54% | -8.90% | 65.71% | -31.63% | 14.19% |
| Operating Income | -46.60% | 148.29% | 14.64% | 228.39% | 311.50% |
| Income Before Tax | -41.74% | 129.09% | 21.15% | 213.85% | 323.56% |
| Income Tax Expenses | -119.11% | 820.29% | 18.12% | 315.18% | 356.39% |
| Earnings from Continuing Operations | -27.22% | 107.44% | 21.24% | 207.45% | 274.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.22% | 107.44% | 21.24% | 207.45% | 274.73% |
| EBIT | -46.60% | 148.29% | 14.64% | 228.39% | 311.50% |
| EBITDA | -42.06% | 172.68% | 16.21% | 242.27% | 373.07% |
| EPS Basic | -32.50% | 106.98% | 24.96% | 211.18% | 271.88% |
| Normalized Basic EPS | -45.87% | 127.32% | 24.94% | 217.72% | 319.46% |
| EPS Diluted | -1.00% | 106.64% | 24.96% | 176.44% | 169.44% |
| Normalized Diluted EPS | -41.55% | 126.29% | 24.94% | 179.20% | 331.25% |
| Average Basic Shares Outstanding | 7.79% | 7.31% | 4.90% | -3.30% | 1.75% |
| Average Diluted Shares Outstanding | -0.50% | 10.86% | 4.90% | 43.67% | -3.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |